Events
Resources
About us
Capabilities
Capabilities
Overview
Biologics
Drug device combinations
Sterile Injectables
Soft gelatin capsules
Facilities
Overview
Integrated DS & DP Facility
Global R&D Facility
Sterile Injectable Facility
Penicillin Injectable Facility
Soft Gelatin Facility
Regulatory & Quality
Regulatory services
Quality
Investors relations
Overview
Financial reports
Shareholder information
Corporate governance
Press releases
Stock exchange intimation
Disclosures under regulation 46 LODR
Scheme of arrangement 2024
Scheme of arrangements 2025
Policies
Careers
Working at OneSource
Notice to Job Seekers
News room
Press releases
Contact us
Events
Resources
Scheme of arrangements 2024
Scheme of arrangements 2024
Listing Approval
BSE_Listing Approval
BSE_Trading Approval
NSE_Listing Approval
Draft Scheme
Valuation Report
SHP Stelis Pre Post without PAN
Audited Financials Summary and AR
Stelis Accounting Certificate
Fairness Report
No-Objection Letter of the Stock Exchange(s)
Audited financials – OneSource FY 2021-22
Audited financials – OneSource FY 2022-23
Audited financials – OneSource FY 2023-24
NCLT Meeting
Onesource_Notice_to_Equity_Shareholders
Onesource-Notice-to-SC-0608-1-51_v1-1
Notice-to-Unsecured-Creditors_Onesource_
Information Memorandum
Stay informed
Don’t miss out on the latest news, results and key updates from OneSource.
Email
(Required)